胃癌高通量测序临床应用中国专家共识  

Chinese expert consensus on the clinical application of next-generation sequencing for gastric cancer

作　　者：中国抗癌协会胃癌专业委员会 徐惠绵[2] 梁寒 聂勇战 王振宁[2] 张小田 李凯[2] 曲秀娟[2] 白莉[6] 陆元志 China Anti-Cancer Association Commitee of Gastric Cancer

机构地区：[1]不详 [2]中国医科大学附属第一医院 [3]天津医科大学肿瘤医院 [4]空军军医大学西京医院 [5]北京大学肿瘤医院 [6]中国人民解放军总医院 [7]暨南大学附属第一医院

出　　处：《中国肿瘤临床》2023年第6期309-318,共10页Chinese Journal of Clinical Oncology

摘　　要：胃癌是消化系统最常见的恶性肿瘤之一,异质性较强,具有复杂的分子特征。HER2、MSI、TMB和NTRK融合等肿瘤相关标志物及分子病理学检测革新了胃癌诊疗模式。根据患者的病理特征和基因检测结果进一步筛选靶向和免疫药物的潜在获益人群,是胃癌精准治疗的未来发展方向。高通量测序(next-generation sequencing,NGS)在胃癌诊断、治疗方案选择、预后监测中发挥着日益重要的作用。然而,国内目前对胃癌NGS的理解与应用尚有不足。中国抗癌协会胃癌专业委员会专家组基于循证医学证据制定《胃癌高通量测序临床应用中国专家共识》,旨在提高中国临床医生与患者对于胃癌NGS的认识,以指导与规范其在国内的临床应用。Gastric cancer is one of the most common malignant tumors in the digestive system,with high heterogeneity and complex molecular characteristics.The emergence of tumor-associated biomarkers,such as HER2,MSI,TMB,and NTRK fusion,and molecular pathological diagnostics have revolutionized the diagnosis and treatment methods of gastric cancer.Screening potential beneficiaries of targeted therapies and immunotherapies based on pathological characteristics and genetic testing results may be a future direction for developing precise treatments for gastric cancer.Next-generation sequencing(NGS)plays an increasingly important role in diagnosing,selecting treatment strategies,and prognostic monitoring of gastric cancer.However,the NGS of gastric cancer remains poorly understood in China.Hence,China Anti-Cancer Association Commitee of Gastric Cancer formulated the Chinese expert consensus on the NGS of gastric cancer based on evidence-based medicine to improve the understanding of clinicians and patients on the NGS of gastric cancer and to guide and standardize its clinical applications in China.

关 键 词：胃癌 精准诊疗 高通量测序 专家共识 

分 类 号：R735.2[医药卫生—肿瘤]